John Jerome Tosh, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 602 N Acadia Rd, Thibodaux, LA 70301 Phone: 504-837-8000 |
Blainey J. Nicholas, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 602 N Acadia Rd, Thibodaux, LA 70301 Phone: 504-837-8000 |
Michael Straney, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 305 E 1st St, Thibodaux, LA 70301 Phone: 985-228-6028 |
Chris Allen Authement, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 602 N Acadia Rd, Thibodaux, LA 70301 Phone: 504-837-8000 |
Quan Shi, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 602 N Acadia Rd, Thibodaux, LA 70301 Phone: 985-447-5500 |
Dr. Maxime Demers, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 602 N Acadia Rd, Thibodaux, LA 70301 Phone: 985-447-5500 |
Dr. Mark Philip Saigh, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 602 N Acadia Rd, Thibodaux, LA 70301 Phone: 985-447-5500 |
Daniel Samet, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 602 N Acadia Rd, Thibodaux, LA 70301 Phone: 914-787-9004 |
News Archive
Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.
Few Americans can tell you how much sodium they should consume each day and most aren't concerned with their personal sodium intake. According to the 2011 International Food Information Council Sodium Survey, 59 percent of Americans say they're not concerned about their sodium intake, consistent with findings in 2009.
IRIS International, Inc., a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, announced today the launch of its new and improved corporate website at www.proiris.com, featuring a newly designed homepage and enhanced navigation tools with access to the latest company information.
Sanofi-aventis and Regeneron Pharmaceuticals, Inc. today announced the discontinuation of the Phase 3 trial that evaluated aflibercept (VEGF Trap) plus gemcitabine versus placebo plus gemcitabine for the first-line treatment of metastatic pancreatic cancer (VANILLA), based on the recommendations by an Independent Data Monitoring Committee (IDMC).
› Verified 8 days ago